Titan Pharmaceuticals, Inc. TN7.F Stock
Titan Pharmaceuticals, Inc. Price Chart
Titan Pharmaceuticals, Inc. TN7.F Financial and Trading Overview
| Titan Pharmaceuticals, Inc. stock price | 0.37 EUR |
| Previous Close | 0.7 EUR |
| Open | 0.68 EUR |
| Bid | 0.68 EUR x N/A |
| Ask | 0.7 EUR x N/A |
| Day's Range | 0.68 - 0.68 EUR |
| 52 Week Range | 0.5 - 1.53 EUR |
| Volume | 93 EUR |
| Avg. Volume | 33 EUR |
| Market Cap | 10.3M EUR |
| Beta (5Y Monthly) | 1.096478 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7 EUR |
TN7.F Valuation Measures
| Enterprise Value | 9.31M EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.5672269 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 22.246572 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 20.104 |
| Enterprise Value/EBITDA | -1.063 |
Trading Information
Titan Pharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 1.096478 |
| 52-Week Change | 33.94% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.53 EUR |
| 52 Week Low | 0.5 EUR |
| 50-Day Moving Average | 0.7 EUR |
| 200-Day Moving Average | 0.88 EUR |
TN7.F Share Statistics
| Avg. Volume (3 month) | 33 EUR |
| Avg. Daily Volume (10-Days) | 159 EUR |
| Shares Outstanding | 15.02M |
| Float | 11.21M |
| Short Ratio | N/A |
| % Held by Insiders | 25.32% |
| % Held by Institutions | 9.73% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2028.72% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -94.035% |
| Return on Equity (ttm) | -246.79% |
Income Statement
| Revenue (ttm) | 463K EUR |
| Revenue Per Share (ttm) | 0.03 EUR |
| Quarterly Revenue Growth (yoy) | -49.00000000000000000000000000000000% |
| Gross Profit (ttm) | N/A |
| EBITDA | -8756000 EUR |
| Net Income Avi to Common (ttm) | -9341000 EUR |
| Diluted EPS (ttm) | -0.59 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.14M EUR |
| Total Cash Per Share (mrq) | 0.08 EUR |
| Total Debt (mrq) | 158K EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.729 |
| Book Value Per Share (mrq) | -0.021 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7118000 EUR |
| Levered Free Cash Flow (ttm) | -3245625 EUR |
Profile of Titan Pharmaceuticals, Inc.
| Country | Germany |
| State | CA |
| City | South San Francisco |
| Address | 400 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | 650 244 4990 |
| Website | https://www.titanpharm.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4 |
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Q&A For Titan Pharmaceuticals, Inc. Stock
What is a current TN7.F stock price?
Titan Pharmaceuticals, Inc. TN7.F stock price today per share is 0.37 EUR.
How to purchase Titan Pharmaceuticals, Inc. stock?
You can buy TN7.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Titan Pharmaceuticals, Inc.?
The stock symbol or ticker of Titan Pharmaceuticals, Inc. is TN7.F.
Which industry does the Titan Pharmaceuticals, Inc. company belong to?
The Titan Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Titan Pharmaceuticals, Inc. have in circulation?
The max supply of Titan Pharmaceuticals, Inc. shares is 753.31K.
What is Titan Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Titan Pharmaceuticals, Inc. PE Ratio is 0.00000000 now.
What was Titan Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Titan Pharmaceuticals, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Titan Pharmaceuticals, Inc. company belong to?
The Titan Pharmaceuticals, Inc. sector is Healthcare.